Analysts expect that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report $3.73 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings, with the highest sales estimate coming in at $10.00 million and the lowest estimate coming in at $500,000.00. Arrowhead Pharmaceuticals reported sales of $8.71 million in the same quarter last year, which indicates a negative year over year growth rate of 57.2%. The company is scheduled to announce its next earnings report after the market closes on Tuesday, December 11th.
On average, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $10.37 million for the current financial year, with estimates ranging from $5.40 million to $15.60 million. For the next year, analysts expect that the firm will post sales of $38.07 million, with estimates ranging from $200,000.00 to $109.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Arrowhead Pharmaceuticals.
A number of brokerages have issued reports on ARWR. BidaskClub cut Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 16th. Chardan Capital reaffirmed a “buy” rating and issued a $17.50 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 13th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 4th. William Blair reaffirmed an “outperform” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 17th. Finally, Cantor Fitzgerald upped their target price on Arrowhead Pharmaceuticals from $18.00 to $24.00 and gave the stock an “overweight” rating in a report on Thursday, October 4th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $21.45.
Shares of ARWR stock opened at $13.13 on Friday. The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals has a twelve month low of $3.01 and a twelve month high of $22.39. The firm has a market cap of $1.19 billion, a P/E ratio of -28.45 and a beta of 2.05.
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 81,500 shares of the company’s stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $14.39, for a total value of $1,172,785.00. Following the completion of the transaction, the chief executive officer now owns 1,727,755 shares of the company’s stock, valued at approximately $24,862,394.45. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Douglas B. Given sold 3,000 shares of the company’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $12.74, for a total value of $38,220.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 215,637 shares of company stock valued at $2,980,043. Insiders own 4.60% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of ARWR. Amalgamated Bank purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $181,000. Janney Montgomery Scott LLC grew its position in shares of Arrowhead Pharmaceuticals by 28.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 25,200 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 5,650 shares during the last quarter. CIBC Private Wealth Group LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $1,088,000. State of Wisconsin Investment Board purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $1,206,000. Finally, EAM Investors LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $1,151,000. 63.33% of the stock is owned by institutional investors and hedge funds.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Featured Article: Systematic Risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.